QQQ ()
DIA ()
SPY ()
TLT ()
GLD ()
$ na
-- x --
-- x --
-- - --
-- - --
--
na
--
--
--
TBD
--
-- (--)
--
TBD --
How to Read 10-K & 10-Q Reports To View SEC Filing Reports, Please Register or Sign In
# Filing Date Period End Date Type Report Link
No Data found
Guide for Analyst Ratings To View Analyst Ratings, Please Register or Sign In
# Date Analyst Firm Upside/Downside Price Target Change Rating Change Current Rating

News

OPINIONS

 why-oragenics-ogen-stock-is-getting-hammered

Oragenics shares are trading lower by 47% during Wednesday's session. The company announced a $4.45 million public offering.

 oragenics-provides-update-on-onp-002-intended-to-treat-concussion-and-receives-notice-of-non-compliance-with-nyse-american-listing-standards

Oragenics, Inc. (NYSE:OGEN) ("the Company"), a company focused on developing unique, intranasal pharmaceuticals for the...

 oragenics-shows-onp-002-for-treatment-of-concussions-stable-across-temperature-range

• ONP-002 stability eliminates need for cumbersome cold storage• No FDA-approved pharmaceutical treatment available for concussion

 why-oragenics-ogen-shares-are-falling

Oragenics shares are trading lower by 21% during Tuesday's session. The company announced pricing of its public offering.

CLASS ACTION DEADLINES - JOIN NOW!

NEW CASE INVESTIGATION